Reseach Progress and Future of Phage Therapy in Klebsiella Pneumoniae Infection

Abstract

Bacteriophages are widely found in nature and can specifically lyse bacterial viruses. Because of the extensive use and abuse of antibiotics, bacterial resistance has become a global problem. Klebsiella pneumoniae is one of the most common clinical drug-resistant bacteria, and the incidence is increasing year by year. Because many strains of Klebsiella pneumoniae are multidrug-resistant, treatment has been difficult. And this resistance has been increasing in recent years, adding to this many new difficulties due to the misuse of antibiotics. The phage can be a new way treat Klebsiella pneumoniae by lysis, which is non-toxic, non-secondary drug resistance, highly specific and penetrating, however, it has not been widely used in clinical practice and only a few cases have been reported. Through the in-depth study of phages, can play an important role in drug-resistant Klebsiella pneumoniae. The paper will introduce the characteristic Klebsiella pneumoniae and phage therapy, and also summarize development of Current animal models and clinical trials of phage therapy in Klebsiella pneumoniae.